Apramycin

Identification

Name
Apramycin
Accession Number
DB04626
Type
Small Molecule
Groups
Experimental, Vet approved
Description

Apramycin is an aminoglycoside antibiotic and has a bactericidal action against many gram-negative bacteria. Apramycin is a structurally unique antibiotic that contains a bicyclic sugar moiety and a monosubstituted deoxystreptamine. It is not approved for use in humans.

Structure
Thumb
Synonyms
  • Nebramycin II
External IDs
EL-857
Product Ingredients
IngredientUNIICASInChI Key
Apramycin sulfate8UYL6NAZ3Q65710-07-8Not applicable
Categories
UNII
388K3TR36Z
CAS number
37321-09-8
Weight
Average: 539.5771
Monoisotopic: 539.280257179
Chemical Formula
C21H41N5O11
InChI Key
XZNUGFQTQHRASN-XQENGBIVSA-N
InChI
InChI=1S/C21H41N5O11/c1-26-11-14(30)18-8(33-20(11)37-21-16(32)13(29)10(25)9(4-27)34-21)3-7(24)19(36-18)35-17-6(23)2-5(22)12(28)15(17)31/h5-21,26-32H,2-4,22-25H2,1H3/t5-,6+,7-,8+,9-,10-,11+,12+,13+,14-,15-,16-,17-,18+,19+,20-,21-/m1/s1
IUPAC Name
(2R,3R,4S,5S,6S)-2-{[(2R,3S,4R,4aR,6S,7R,8aS)-7-amino-6-{[(1R,2R,3S,4R,6S)-4,6-diamino-2,3-dihydroxycyclohexyl]oxy}-4-hydroxy-3-(methylamino)-octahydropyrano[3,2-b]pyran-2-yl]oxy}-5-amino-6-(hydroxymethyl)oxane-3,4-diol
SMILES
CN[C@H]1[C@@H](O)[C@H]2O[C@H](O[C@@H]3[C@@H](N)C[C@@H](N)[C@H](O)[C@H]3O)[C@H](N)C[C@@H]2O[C@@H]1O[C@H]1O[C@H](CO)[C@@H](N)[C@H](O)[C@H]1O

Pharmacology

Indication

For the treatment of bacterial infections in animals.

Pharmacodynamics
Not Available
Mechanism of action

Apramycin stands out among aminoglycosides for its mechanism of action which is based on blocking translocation and its ability to bind also to the eukaryotic decoding site despite differences in key residues required for apramycin recognition by the bacterial target. The drug binds in the deep groove of the RNA which forms a continuously stacked helix comprising non-canonical C.A and G.A base pairs and a bulged-out adenine. The binding mode of apramycin at the human decoding-site RNA is distinct from aminoglycoside recognition of the bacterial target, suggesting a molecular basis for the actions of apramycin in eukaryotes and bacteria.

TargetActionsOrganism
U16S rRNANot AvailableEnteric bacteria and other eubacteria
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Enteric bacteria and other eubacteria
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may decrease the excretion rate of Apramycin which could result in a higher serum level.Investigational
AceclofenacAceclofenac may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Investigational
AcemetacinAcemetacin may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Experimental, Investigational
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Apramycin.Approved
AcetyldigoxinThe serum concentration of Acetyldigoxin can be decreased when it is combined with Apramycin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Vet Approved
AdapaleneAdapalene may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved
AlclofenacAlclofenac may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Withdrawn
AlcuroniumApramycin may increase the respiratory depressant activities of Alcuronium.Experimental
Alendronic acidApramycin may increase the hypocalcemic activities of Alendronic acid.Approved
AlminoprofenAlminoprofen may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental
AmdinocillinThe serum concentration of Apramycin can be decreased when it is combined with Amdinocillin.Investigational, Withdrawn
AmikacinThe risk or severity of adverse effects can be increased when Amikacin is combined with Apramycin.Approved, Investigational, Vet Approved
AmoxicillinThe serum concentration of Apramycin can be decreased when it is combined with Amoxicillin.Approved, Vet Approved
Amphotericin BAmphotericin B may increase the nephrotoxic activities of Apramycin.Approved, Investigational
AmpicillinThe serum concentration of Apramycin can be decreased when it is combined with Ampicillin.Approved, Vet Approved
AndrographolideAndrographolide may decrease the excretion rate of Apramycin which could result in a higher serum level.Investigational
AnisodamineAnisodamine may decrease the excretion rate of Apramycin which could result in a higher serum level.Investigational
AntipyrineAntipyrine may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Investigational
ApocyninApocynin may decrease the excretion rate of Apramycin which could result in a higher serum level.Investigational
ApremilastApremilast may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Investigational
AspoxicillinThe serum concentration of Apramycin can be decreased when it is combined with Aspoxicillin.Experimental
AtracuriumApramycin may increase the respiratory depressant activities of Atracurium.Approved, Experimental, Investigational
Atracurium besylateApramycin may increase the respiratory depressant activities of Atracurium besylate.Approved
AtropineThe therapeutic efficacy of Atropine can be decreased when used in combination with Apramycin.Approved, Vet Approved
AzapropazoneAzapropazone may decrease the excretion rate of Apramycin which could result in a higher serum level.Withdrawn
AzelastineAzelastine may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved
AzidocillinThe serum concentration of Apramycin can be decreased when it is combined with Azidocillin.Approved
AzlocillinThe serum concentration of Apramycin can be decreased when it is combined with Azlocillin.Approved
AzosemideThe serum concentration of Apramycin can be increased when it is combined with Azosemide.Investigational
BacampicillinThe serum concentration of Apramycin can be decreased when it is combined with Bacampicillin.Approved, Investigational
BacitracinThe risk or severity of nephrotoxicity can be increased when Apramycin is combined with Bacitracin.Approved, Vet Approved
BalsalazideBalsalazide may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Apramycin.Investigational
BendazacBendazac may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental
BenorilateBenorilate may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental
BenoxaprofenBenoxaprofen may decrease the excretion rate of Apramycin which could result in a higher serum level.Withdrawn
BenzatropineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Apramycin.Approved
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Apramycin.Approved, Illicit
BenzydamineBenzydamine may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Apramycin.Approved
BenzylpenicillinThe serum concentration of Apramycin can be decreased when it is combined with Benzylpenicillin.Approved, Vet Approved
Benzylpenicilloyl PolylysineThe serum concentration of Apramycin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
BevoniumBevonium may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental
Botulinum Toxin Type AApramycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BApramycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved, Investigational
BromfenacBromfenac may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Apramycin.Approved
BucillamineBucillamine may decrease the excretion rate of Apramycin which could result in a higher serum level.Investigational
BufexamacBufexamac may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Experimental
BumadizoneBumadizone may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental
BumetanideThe serum concentration of Apramycin can be increased when it is combined with Bumetanide.Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Apramycin.Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Apramycin.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Apramycin.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Investigational
CarbenicillinThe serum concentration of Apramycin can be decreased when it is combined with Carbenicillin.Approved, Investigational
Carbenicillin indanylThe serum concentration of Apramycin can be decreased when it is combined with Carbenicillin indanyl.Approved, Investigational
CarboplatinApramycin may increase the ototoxic activities of Carboplatin.Approved
CarfecillinThe serum concentration of Apramycin can be decreased when it is combined with Carfecillin.Experimental
CarprofenCarprofen may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental
CefaclorCefaclor may increase the nephrotoxic activities of Apramycin.Approved
CefamandoleCefamandole may increase the nephrotoxic activities of Apramycin.Approved, Investigational
CefbuperazoneCefbuperazone may increase the nephrotoxic activities of Apramycin.Experimental
CefcapeneCefcapene may increase the nephrotoxic activities of Apramycin.Experimental
CefdinirCefdinir may increase the nephrotoxic activities of Apramycin.Approved
CefditorenCefditoren may increase the nephrotoxic activities of Apramycin.Approved, Investigational
CefepimeCefepime may increase the nephrotoxic activities of Apramycin.Approved, Investigational
CefetametCefetamet may increase the nephrotoxic activities of Apramycin.Experimental
CefiximeCefixime may increase the nephrotoxic activities of Apramycin.Approved, Investigational
CefmenoximeCefmenoxime may increase the nephrotoxic activities of Apramycin.Approved
CefmetazoleCefmetazole may increase the nephrotoxic activities of Apramycin.Approved, Investigational
CefminoxCefminox may increase the nephrotoxic activities of Apramycin.Approved
CefodizimeCefodizime may increase the nephrotoxic activities of Apramycin.Experimental
CefonicidCefonicid may increase the nephrotoxic activities of Apramycin.Approved, Investigational
CefoperazoneCefoperazone may increase the nephrotoxic activities of Apramycin.Approved, Investigational
CeforanideCeforanide may increase the nephrotoxic activities of Apramycin.Approved
CefotaximeCefotaxime may increase the nephrotoxic activities of Apramycin.Approved
CefotetanCefotetan may increase the nephrotoxic activities of Apramycin.Approved
CefotiamCefotiam may increase the nephrotoxic activities of Apramycin.Approved, Investigational
CefoxitinCefoxitin may increase the nephrotoxic activities of Apramycin.Approved
CefozopranCefozopran may increase the nephrotoxic activities of Apramycin.Experimental
CefpiramideCefpiramide may increase the nephrotoxic activities of Apramycin.Approved
CefpiromeCefpirome may increase the nephrotoxic activities of Apramycin.Approved
CefpodoximeCefpodoxime may increase the nephrotoxic activities of Apramycin.Approved, Vet Approved
CefprozilCefprozil may increase the nephrotoxic activities of Apramycin.Approved
CefsulodinCefsulodin may increase the nephrotoxic activities of Apramycin.Experimental
CeftazidimeCeftazidime may increase the nephrotoxic activities of Apramycin.Approved
CeftibutenCeftibuten may increase the nephrotoxic activities of Apramycin.Approved, Investigational
CeftizoximeCeftizoxime may increase the nephrotoxic activities of Apramycin.Approved, Investigational
CeftriaxoneCeftriaxone may increase the nephrotoxic activities of Apramycin.Approved
CefuroximeCefuroxime may increase the nephrotoxic activities of Apramycin.Approved
CelecoxibCelecoxib may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Apramycin.Approved
ChloroquineChloroquine may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Apramycin.Approved
ChlorthalidoneThe serum concentration of Apramycin can be increased when it is combined with Chlorthalidone.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved
CisatracuriumApramycin may increase the respiratory depressant activities of Cisatracurium.Approved
CisplatinCisplatin may increase the nephrotoxic activities of Apramycin.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Apramycin.Approved, Investigational
ClindamycinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Apramycin.Approved, Vet Approved
Clodronic AcidApramycin may increase the hypocalcemic activities of Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinClonixin may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved
CloxacillinThe serum concentration of Apramycin can be decreased when it is combined with Cloxacillin.Approved, Investigational, Vet Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Apramycin.Approved, Illicit
ColistimethateApramycin may increase the nephrotoxic activities of Colistimethate.Approved, Vet Approved
CurcuminCurcumin may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Investigational
CyclacillinThe serum concentration of Apramycin can be decreased when it is combined with Cyclacillin.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Apramycin.Approved
CyclosporineThe risk or severity of adverse effects can be increased when Apramycin is combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinThe serum concentration of Cymarin can be decreased when it is combined with Apramycin.Experimental
DecamethoniumApramycin may increase the respiratory depressant activities of Decamethonium.Approved
DeslanosideThe serum concentration of Deslanoside can be decreased when it is combined with Apramycin.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Apramycin is combined with Desvenlafaxine.Approved, Investigational
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Apramycin.Approved
DiclofenacThe risk or severity of nephrotoxicity can be increased when Diclofenac is combined with Apramycin.Approved, Vet Approved
DicloxacillinThe serum concentration of Apramycin can be decreased when it is combined with Dicloxacillin.Approved, Investigational, Vet Approved
DifenpiramideDifenpiramide may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental
DiflunisalDiflunisal may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Investigational
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Apramycin.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Apramycin.Approved
Digoxin Immune Fab (Ovine)The serum concentration of Digoxin Immune Fab (Ovine) can be decreased when it is combined with Apramycin.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Apramycin.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Apramycin.Approved, Investigational
Domoic AcidApramycin may increase the respiratory depressant activities of Domoic Acid.Experimental
DotarizineThe risk or severity of adverse effects can be increased when Apramycin is combined with Dotarizine.Investigational
DoxacuriumApramycin may increase the respiratory depressant activities of Doxacurium chloride.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Apramycin.Approved, Vet Approved
DroxicamDroxicam may decrease the excretion rate of Apramycin which could result in a higher serum level.Withdrawn
DuvelisibDuvelisib may decrease the excretion rate of Apramycin which could result in a higher serum level.Investigational
E-6201E-6201 may decrease the excretion rate of Apramycin which could result in a higher serum level.Investigational
EperisoneThe risk or severity of adverse effects can be increased when Eperisone is combined with Apramycin.Approved, Investigational
EpicillinThe serum concentration of Apramycin can be decreased when it is combined with Epicillin.Experimental
EpirizoleEpirizole may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved
Etacrynic acidThe serum concentration of Apramycin can be increased when it is combined with Etacrynic acid.Approved, Investigational
EtanerceptEtanercept may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Investigational
EthanolApramycin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthenzamideEthenzamide may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Apramycin.Approved
Etidronic acidApramycin may increase the hypocalcemic activities of Etidronic acid.Approved
EtodolacEtodolac may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Investigational
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Apramycin.Approved
EtoricoxibEtoricoxib may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the excretion rate of Apramycin which could result in a higher serum level.Investigational, Nutraceutical
ExisulindExisulind may decrease the excretion rate of Apramycin which could result in a higher serum level.Investigational
FelbinacFelbinac may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental
FenbufenFenbufen may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved
FenoprofenFenoprofen may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Apramycin.Approved, Illicit, Investigational, Vet Approved
FentiazacFentiazac may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental
FeprazoneFeprazone may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental
Ferulic acidFerulic acid may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental
FloctafenineFloctafenine may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Withdrawn
FlomoxefFlomoxef may increase the nephrotoxic activities of Apramycin.Investigational
FlucloxacillinThe serum concentration of Apramycin can be decreased when it is combined with Flucloxacillin.Approved, Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Apramycin.Approved
FlunixinFlunixin may decrease the excretion rate of Apramycin which could result in a higher serum level.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental
FluoxetineThe risk or severity of adverse effects can be increased when Apramycin is combined with Fluoxetine.Approved, Vet Approved
FlurbiprofenFlurbiprofen may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Apramycin.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Apramycin.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Apramycin is combined with Fluvoxamine.Approved, Investigational
FoscarnetFoscarnet may increase the nephrotoxic activities of Apramycin.Approved
FurosemideThe serum concentration of Apramycin can be increased when it is combined with Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Apramycin.Approved, Investigational
GallamineApramycin may increase the respiratory depressant activities of Gallamine.Experimental
Gallamine TriethiodideApramycin may increase the respiratory depressant activities of Gallamine Triethiodide.Approved
GitoformateThe serum concentration of Gitoformate can be decreased when it is combined with Apramycin.Experimental
GuacetisalGuacetisal may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Apramycin.Approved, Investigational
HigenamineHigenamine may decrease the excretion rate of Apramycin which could result in a higher serum level.Investigational
HydrocodoneApramycin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Apramycin can be increased when it is combined with Hydroflumethiazide.Approved, Investigational
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Apramycin.Approved
HyoscyamineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Apramycin.Approved
IbandronateThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Apramycin is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of nephrotoxicity can be increased when Ibuprofen is combined with Apramycin.Approved
IbuproxamIbuproxam may decrease the excretion rate of Apramycin which could result in a higher serum level.Withdrawn
IcatibantIcatibant may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Investigational
Imidazole salicylateImidazole salicylate may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental
IndobufenIndobufen may decrease the excretion rate of Apramycin which could result in a higher serum level.Investigational
IndomethacinIndomethacin may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Investigational
IndoprofenIndoprofen may decrease the excretion rate of Apramycin which could result in a higher serum level.Withdrawn
IpratropiumThe therapeutic efficacy of Ipratropium can be decreased when used in combination with Apramycin.Approved
IsoxicamIsoxicam may decrease the excretion rate of Apramycin which could result in a higher serum level.Withdrawn
KebuzoneKebuzone may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental
KetoprofenKetoprofen may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Vet Approved
KetorolacThe risk or severity of nephrotoxicity can be increased when Ketorolac is combined with Apramycin.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Apramycin.Approved, Investigational
Lanatoside CThe serum concentration of Lanatoside C can be decreased when it is combined with Apramycin.Experimental
LatamoxefLatamoxef may increase the nephrotoxic activities of Apramycin.Approved, Investigational
LeflunomideLeflunomide may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Apramycin.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Apramycin.Approved
LisofyllineLisofylline may decrease the excretion rate of Apramycin which could result in a higher serum level.Investigational
LonazolacLonazolac may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental
LoracarbefLoracarbef may increase the nephrotoxic activities of Apramycin.Investigational, Withdrawn
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Apramycin.Approved, Investigational
LornoxicamLornoxicam may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Investigational
LoxoprofenLoxoprofen may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Investigational
LumiracoxibLumiracoxib may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Investigational
Magnesium carbonateThe risk or severity of adverse effects can be increased when Apramycin is combined with Magnesium carbonate.Approved, Investigational
Magnesium citrateThe risk or severity of adverse effects can be increased when Apramycin is combined with Magnesium citrate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Apramycin is combined with Magnesium hydroxide.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved
Magnesium sulfateThe therapeutic efficacy of Apramycin can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Apramycin is combined with Magnesium Trisilicate.Approved
MannitolMannitol may increase the nephrotoxic activities of Apramycin.Approved, Investigational
MasoprocolMasoprocol may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Investigational
MecamylamineApramycin may increase the neuromuscular blocking activities of Mecamylamine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Apramycin.Approved
Meclofenamic acidMeclofenamic acid may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved
MeloxicamMeloxicam may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Vet Approved
MesalazineMesalazine may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved
MetamizoleMetamizole may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Investigational, Withdrawn
MetampicillinThe serum concentration of Apramycin can be decreased when it is combined with Metampicillin.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Apramycin.Approved
MethyclothiazideThe serum concentration of Apramycin can be increased when it is combined with Methyclothiazide.Approved
MeticillinThe serum concentration of Apramycin can be decreased when it is combined with Meticillin.Approved, Investigational
MetildigoxinThe serum concentration of Metildigoxin can be decreased when it is combined with Apramycin.Experimental
MetocurineApramycin may increase the respiratory depressant activities of Metocurine.Approved
Metocurine IodideApramycin may increase the respiratory depressant activities of Metocurine Iodide.Approved, Withdrawn
MezlocillinThe serum concentration of Apramycin can be decreased when it is combined with Mezlocillin.Approved, Investigational
MivacuriumApramycin may increase the respiratory depressant activities of Mivacurium.Approved
MizoribineMizoribine may decrease the excretion rate of Apramycin which could result in a higher serum level.Investigational
MofebutazoneMofebutazone may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved
NabumetoneNabumetone may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved
NafamostatNafamostat may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Investigational
NafcillinThe serum concentration of Apramycin can be decreased when it is combined with Nafcillin.Approved, Investigational
NaftifineNaftifine may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved
NaproxenThe risk or severity of nephrotoxicity can be increased when Naproxen is combined with Apramycin.Approved, Vet Approved
NeomycinThe risk or severity of adverse effects can be increased when Neomycin is combined with Apramycin.Approved, Vet Approved
NeosaxitoxinApramycin may increase the respiratory depressant activities of Neosaxitoxin.Investigational
NepafenacNepafenac may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Apramycin is combined with Nicotine.Approved
NifenazoneNifenazone may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental
Niflumic AcidNiflumic Acid may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved
NimesulideThe risk or severity of nephrotoxicity can be increased when Nimesulide is combined with Apramycin.Approved, Investigational, Withdrawn
NitroaspirinNitroaspirin may decrease the excretion rate of Apramycin which could result in a higher serum level.Investigational
OleandrinThe serum concentration of Oleandrin can be decreased when it is combined with Apramycin.Experimental, Investigational
OlopatadineOlopatadine may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved
OlsalazineOlsalazine may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Apramycin.Approved
OrgoteinOrgotein may decrease the excretion rate of Apramycin which could result in a higher serum level.Vet Approved
OtiloniumThe therapeutic efficacy of Otilonium can be decreased when used in combination with Apramycin.Experimental, Investigational
OuabainThe serum concentration of Ouabain can be decreased when it is combined with Apramycin.Approved
OxacillinThe serum concentration of Apramycin can be decreased when it is combined with Oxacillin.Approved, Investigational
OxaprozinOxaprozin may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Apramycin.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Apramycin.Approved, Investigational, Vet Approved
OxyphenbutazoneOxyphenbutazone may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Withdrawn
PalmidrolPalmidrol may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Nutraceutical
PamidronateApramycin may increase the hypocalcemic activities of Pamidronate.Approved
PancuroniumApramycin may increase the respiratory depressant activities of Pancuronium.Approved
ParecoxibParecoxib may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved
ParomomycinThe risk or severity of adverse effects can be increased when Paromomycin is combined with Apramycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Apramycin is combined with Paroxetine.Approved, Investigational
ParthenolideParthenolide may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Investigational
PenamecillinThe serum concentration of Apramycin can be decreased when it is combined with Penamecillin.Experimental
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Apramycin.Experimental
PeruvosideThe serum concentration of Peruvoside can be decreased when it is combined with Apramycin.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Apramycin.Approved, Investigational
PhenoxymethylpenicillinThe serum concentration of Apramycin can be decreased when it is combined with Phenoxymethylpenicillin.Approved, Vet Approved
PhenylbutazonePhenylbutazone may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Apramycin.Approved
PimecrolimusPimecrolimus may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Investigational
PipecuroniumApramycin may increase the respiratory depressant activities of Pipecuronium.Approved
PiperacillinThe serum concentration of Apramycin can be decreased when it is combined with Piperacillin.Approved
PiretanideThe serum concentration of Apramycin can be increased when it is combined with Piretanide.Approved
PirfenidonePirfenidone may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Investigational
PiroxicamPiroxicam may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Investigational
PirprofenPirprofen may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental
PivampicillinThe serum concentration of Apramycin can be decreased when it is combined with Pivampicillin.Approved
PivmecillinamThe serum concentration of Apramycin can be decreased when it is combined with Pivmecillinam.Approved
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Apramycin is combined with Polymyxin B Sulfate.Approved, Vet Approved
PramipexoleApramycin may increase the sedative activities of Pramipexole.Approved, Investigational
PranoprofenPranoprofen may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Investigational
PregabalinThe therapeutic efficacy of Apramycin can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
Procaine benzylpenicillinThe serum concentration of Apramycin can be decreased when it is combined with Procaine benzylpenicillin.Approved, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Apramycin.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Apramycin.Approved, Investigational
PropacetamolPropacetamol may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Investigational
PropicillinThe serum concentration of Apramycin can be decreased when it is combined with Propicillin.Experimental
PropyphenazonePropyphenazone may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental
ProquazoneProquazone may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental
ProscillaridinThe serum concentration of Proscillaridin can be decreased when it is combined with Apramycin.Experimental
PseudoephedrineThe risk or severity of adverse effects can be increased when Apramycin is combined with Pseudoephedrine.Approved
PTC299PTC299 may decrease the excretion rate of Apramycin which could result in a higher serum level.Investigational
PyrantelThe therapeutic efficacy of Pyrantel can be increased when used in combination with Apramycin.Approved, Vet Approved
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Apramycin.Approved
QuinethazoneThe serum concentration of Apramycin can be increased when it is combined with Quinethazone.Approved
RapacuroniumApramycin may increase the respiratory depressant activities of Rapacuronium.Withdrawn
ResveratrolResveratrol may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Experimental, Investigational
RisedronateApramycin may increase the hypocalcemic activities of Risedronate.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Apramycin is combined with Rizatriptan.Approved
RocuroniumApramycin may increase the respiratory depressant activities of Rocuronium.Approved
RofecoxibRofecoxib may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Investigational, Withdrawn
RopiniroleApramycin may increase the sedative activities of Ropinirole.Approved, Investigational
SalicylamideSalicylamide may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved
Salicylic acidThe risk or severity of nephrotoxicity can be increased when Salicylic acid is combined with Apramycin.Approved, Investigational, Vet Approved
SalsalateSalsalate may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Apramycin.Approved, Investigational
SemapimodSemapimod may decrease the excretion rate of Apramycin which could result in a higher serum level.Investigational
SeratrodastSeratrodast may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved
SerrapeptaseSerrapeptase may decrease the excretion rate of Apramycin which could result in a higher serum level.Investigational
SRT501SRT501 may decrease the excretion rate of Apramycin which could result in a higher serum level.Investigational
SuccinylcholineApramycin may increase the respiratory depressant activities of Succinylcholine.Approved
SulbenicillinThe serum concentration of Apramycin can be decreased when it is combined with Sulbenicillin.Experimental
SulfasalazineThe risk or severity of nephrotoxicity can be increased when Sulfasalazine is combined with Apramycin.Approved
SulindacThe risk or severity of nephrotoxicity can be increased when Sulindac is combined with Apramycin.Approved, Investigational
SultamicillinThe serum concentration of Apramycin can be decreased when it is combined with Sultamicillin.Approved, Investigational
SumatriptanThe risk or severity of adverse effects can be increased when Apramycin is combined with Sumatriptan.Approved, Investigational
SuprofenSuprofen may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental
TalampicillinThe serum concentration of Apramycin can be decreased when it is combined with Talampicillin.Experimental
TarenflurbilTarenflurbil may decrease the excretion rate of Apramycin which could result in a higher serum level.Investigational
Technetium Tc-99m etidronateApramycin may increase the hypocalcemic activities of Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateApramycin may increase the hypocalcemic activities of Technetium Tc-99m medronate.Approved
TenidapTenidap may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental
Tenofovir disoproxilThe serum concentration of Apramycin can be increased when it is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamTenoxicam may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved
TepoxalinTepoxalin may decrease the excretion rate of Apramycin which could result in a higher serum level.Vet Approved
TeriflunomideTeriflunomide may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved
TetracyclineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Apramycin.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Apramycin.Investigational
Tiaprofenic acidTiaprofenic acid may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved
TicarcillinThe serum concentration of Apramycin can be decreased when it is combined with Ticarcillin.Approved, Investigational, Vet Approved
Tiludronic acidApramycin may increase the hypocalcemic activities of Tiludronic acid.Approved, Investigational, Vet Approved
TinoridineTinoridine may decrease the excretion rate of Apramycin which could result in a higher serum level.Investigational
Tolfenamic AcidThe risk or severity of nephrotoxicity can be increased when Tolfenamic Acid is combined with Apramycin.Approved, Investigational
TolmetinTolmetin may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Apramycin.Approved
TorasemideThe serum concentration of Apramycin can be increased when it is combined with Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Apramycin.Approved, Investigational
TribenosideTribenoside may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental
TrichlormethiazideThe serum concentration of Apramycin can be increased when it is combined with Trichlormethiazide.Approved, Vet Approved
TrimethadioneThe risk or severity of adverse effects can be increased when Trimethadione is combined with Apramycin.Approved
TriptolideTriptolide may decrease the excretion rate of Apramycin which could result in a higher serum level.Investigational
Trolamine salicylateThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Apramycin.Approved
TrospiumThe therapeutic efficacy of Trospium can be decreased when used in combination with Apramycin.Approved
TubocurarineApramycin may increase the respiratory depressant activities of Tubocurarine.Approved
ValdecoxibValdecoxib may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Investigational, Withdrawn
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Apramycin.Approved, Investigational
VancomycinThe risk or severity of adverse effects can be increased when Vancomycin is combined with Apramycin.Approved
VecuroniumThe therapeutic efficacy of Vecuronium can be increased when used in combination with Apramycin.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Apramycin is combined with Venlafaxine.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Vinpocetine is combined with Apramycin.Investigational
ZaltoprofenZaltoprofen may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Apramycin.Approved
ZileutonZileuton may decrease the excretion rate of Apramycin which could result in a higher serum level.Approved, Investigational, Withdrawn
Zoledronic acidThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Apramycin is combined with Zoledronic acid.Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Apramycin is combined with Zolmitriptan.Approved, Investigational
ZolpidemApramycin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZomepiracZomepirac may decrease the excretion rate of Apramycin which could result in a higher serum level.Withdrawn
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Apramycin.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Koji Tomita, Hiroshi Tsukiura, Hiroshi Kawaguchi, "Fermentation process for producing apramycin and nebramycin factor V'." U.S. Patent US4032404, issued December, 1974.

US4032404
General References
  1. Hermann T, Tereshko V, Skripkin E, Patel DJ: Apramycin recognition by the human ribosomal decoding site. Blood Cells Mol Dis. 2007 May-Jun;38(3):193-8. Epub 2007 Jan 29. [PubMed:17258916]
  2. Kondo J, Francois B, Urzhumtsev A, Westhof E: Crystal structure of the Homo sapiens cytoplasmic ribosomal decoding site complexed with apramycin. Angew Chem Int Ed Engl. 2006 May 12;45(20):3310-4. [PubMed:16596680]
  3. Han Q, Zhao Q, Fish S, Simonsen KB, Vourloumis D, Froelich JM, Wall D, Hermann T: Molecular recognition by glycoside pseudo base pairs and triples in an apramycin-RNA complex. Angew Chem Int Ed Engl. 2005 Apr 29;44(18):2694-700. [PubMed:15849690]
External Links
KEGG Drug
D02322
KEGG Compound
C01555
PubChem Compound
3081545
PubChem Substance
46509143
ChemSpider
2339128
ChEBI
2790
ChEMBL
CHEMBL1230961
Therapeutic Targets Database
DNC000243
HET
AM2
Wikipedia
Apramycin
PDB Entries
1yrj / 2g5k / 2m4q / 2oe5 / 2oe8 / 4aqy / 4k31
MSDS
Download (40.6 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
pKa8.5MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility53.3 mg/mLALOGPS
logP-2.8ALOGPS
logP-6.5ChemAxon
logS-1ALOGPS
pKa (Strongest Acidic)12.29ChemAxon
pKa (Strongest Basic)9.73ChemAxon
Physiological Charge5ChemAxon
Hydrogen Acceptor Count16ChemAxon
Hydrogen Donor Count11ChemAxon
Polar Surface Area283.64 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity120.91 m3·mol-1ChemAxon
Polarizability54.29 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8007
Blood Brain Barrier-0.9898
Caco-2 permeable-0.7556
P-glycoprotein substrateSubstrate0.568
P-glycoprotein inhibitor INon-inhibitor0.8164
P-glycoprotein inhibitor IINon-inhibitor0.9619
Renal organic cation transporterNon-inhibitor0.885
CYP450 2C9 substrateNon-substrate0.7737
CYP450 2D6 substrateNon-substrate0.8285
CYP450 3A4 substrateNon-substrate0.544
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9196
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9234
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8708
Ames testAMES toxic0.5193
CarcinogenicityNon-carcinogens0.9671
BiodegradationNot ready biodegradable0.9023
Rat acute toxicity2.2488 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9812
hERG inhibition (predictor II)Non-inhibitor0.8385
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as aminocyclitol glycosides. These are organic compounds containing an amicocyclitol moiety glycosidically linked to a carbohydrate moiety. There are two major classes of aminoglycosides containing a 2-streptamine core. They are called 4,5- and 4,6-disubstituted 2-deoxystreptamines.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Aminocyclitol glycosides
Alternative Parents
Hexoses / Aminocyclitols and derivatives / Cyclohexylamines / Cyclohexanols / Oxanes / 1,3-aminoalcohols / 1,2-aminoalcohols / Oxacyclic compounds / Dialkylamines / Acetals
show 4 more
Substituents
Amino cyclitol glycoside / Hexose monosaccharide / Aminocyclitol or derivatives / Cyclohexylamine / Cyclohexanol / Oxane / Cyclitol or derivatives / Monosaccharide / 1,3-aminoalcohol / Cyclic alcohol
show 17 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
organic heterobicyclic compound, aminoglycoside, 2-deoxystreptamine derivative (CHEBI:2790)

Targets

1. 16S rRNA
Kind
Nucleotide
Organism
Enteric bacteria and other eubacteria
Pharmacological action
Unknown
References
  1. Woodcock J, Moazed D, Cannon M, Davies J, Noller HF: Interaction of antibiotics with A- and P-site-specific bases in 16S ribosomal RNA. EMBO J. 1991 Oct;10(10):3099-103. [PubMed:1915283]
  2. Kondo J, Francois B, Urzhumtsev A, Westhof E: Crystallographic studies of Homo sapiens ribosomal decoding A site complexed with aminoglycosides. Nucleic Acids Symp Ser (Oxf). 2005;(49):253-4. [PubMed:17150729]

Drug created on September 11, 2007 11:49 / Updated on August 02, 2018 07:56